Home | The Oncologist Community

Highlighted Article

Real-World PFS for ALK TKIs in ALK+ NSCLC Patients

Mohammad Jahanzeb, et al., The Oncologist

Patients with non-small cell lung cancer (NSCLC) characterized by ALK rearrangements may benefit from ALK tyrosine kinase inhibitor (TKI) therapies. This article summarizes the characteristics of patients with ALK+ advanced NSCLC treated with ALK TKI therapy, describes treatment pathways and duration for these patients, and examines real-world progression-free survival and treatment discontinuation for patients receiving first-line and second-line ALK TKI therapy overall and for the subgroups of patients with and without pre-existing brain metastasis at ALK TKI initiation.

Discussions with Don S. Dizon

Don S. Dizon is the Director of Women's Cancers at Lifespan Cancer Institute, Founder of The Oncology Sexual Health First Responders Clinic at Lifespan Cancer Institute, and Director of Medical Oncology at Rhode Island Hospital. Dr. Dizon is a Professor of Medicine at the Warren Alpert Medical School of Brown University.

Follow @drdonsdizon

What Doesn’t Kill You Make You Stronger: A Conversation with Ginny Mason

08/18/20

Don Dizon learns about Ginny Mason's experiences as a breast cancer survivor, patient advocate, and nonprofit leader in this month's blog post.

Reflecting Back, Looking Ahead

06/29/20

In this month's blog post, Don Dizon and his colleague Mary Anne Fenton discuss her career in oncology and how the profession has changed over the past 20 years.

Learning to Do Cancer: Words Matter

05/19/20

In this month's blog, Don Dizon and patient advocate Stacey Tinianov reflect on the power words can have when communicating about cancer with patients. They also discuss how the meaning of words can be fluid and dependent on individual context.

As we monitor and respond to the COVID-19 outbreak, we at AlphaMed Press know how important every update and new piece of information is to reaching the goal of ending this pandemic. Below you can find helpful links to the latest research and findings.

Immune-Related Adverse Events

Immunotherapy enhances a cancer patient’s immune system to fight an array of cancers. Immune checkpoint blockade can, however, induce inflammatory side effects known as immune-related Adverse Events (irAE). Because these rare but serious complications need to be quickly detected and properly treated, The Oncologist is devoting a new series designed to enhance the care of patients who may well benefit from therapeutic strategies that involve one or more these powerful immunotherapies.

Read about our irAE collection

PMC: Molecular Tumor Board

Precision Medicine Clinic: Molecular Tumor Board is a case-based series designed to help clinicians optimize molecular testing for their patients. The Editors of The Oncologist encourage institutions to share their findings and experiences to help improve the precision of genomic oncology and fulfill its promise of improved outcomes for patients. This collection highlights a diverse set of patients exhibiting a range of tumor types and mutations.

Read our PMC collection

Cancer Care & the Opioid Crisis

Opioids form the cornerstone of pain management in cancer patients, but the crisis of opioid addiction has resulted in significant challenges facing patients, physicians, lawmakers, and communities across the nation. This series is focused to help clinicians manage the opioid crisis while ensuring adequate pain management for their patients.

Read about our Opioid collection

	08/18/20	Highlights: Pancreatic Cancer, Ovarian Cancer, iRAEs and more
	07/17/20	Highlights: NSCLC, Breast Cancer, Liver Cancer and more
	07/08/20	Celebrating 25 years of The Oncologist
	06/18/20	Regorafenib and Nivolumab in MSS Colorectal Cancer